

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Qiming U.S. Healthcare Fund II, L.P.</u> <hr/> (Last) (First) (Middle) 11100 NE 8TH ST., SUITE 200 <hr/> (Street) BELLEVUE WA 98004 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Jasper Therapeutics, Inc. [JSPR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/27/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Voting Common Stock	01/27/2023		P		2,666,666	A	\$1.5	8,519,648	D ⁽¹⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Qiming U.S. Healthcare Fund II, L.P.

 (Last) (First) (Middle)
 11100 NE 8TH ST., SUITE 200

 (Street)
 BELLEVUE WA 98004

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Qiming U.S. Healthcare GP II, LLC

 (Last) (First) (Middle)
 11100 NE 8TH ST., SUITE 200

 (Street)
 BELLEVUE WA 98004

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MCDADE MARK

 (Last) (First) (Middle)
 C/O QIMING U.S. VENTURES MANAGEMENT, LLC
 11100 NE 8TH ST., SUITE 200

 (City) (State) (Zip)

(Street)	BELLEVUE	WA	98004
(City)	(State)	(Zip)	
1. Name and Address of Reporting Person*			
<u>RIESCHEL GARY E</u>			
(Last)	(First)	(Middle)	
C/O QIMING U.S. VENTURES MANAGEMENT, LLC			
11100 NE 8TH ST., SUITE 200			
(Street)	BELLEVUE	WA	98004
(City)	(State)	(Zip)	

Explanation of Responses:

1. The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Remarks:

Qiming U.S. Healthcare Fund II, L.P., By: Qiming U.S. Healthcare GP II, LLC, its general partner, By /s/ Mark McDade, Managing Partner 04/11/2023

Qiming U.S. Healthcare GP II, LLC, By /s/ Mark McDade, Managing Partner 04/11/2023

/s/ Mark McDade 04/11/2023

/s/ Gary Rieschel 04/11/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.